Terms: = Leukemia AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Treatment
19 results:
1. Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors.
Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
[TBL] [Abstract] [Full Text] [Related]
2. PIN1 and CDK1 cooperatively govern pvhl stability and suppressive functions.
Chen J; Li M; Liu Y; Guan T; Yang X; Wen Y; Zhu Y; Xiao Z; Shen X; Zhang H; Tang H; Liu T
Cell Death Differ; 2023 Apr; 30(4):1082-1095. PubMed ID: 36813923
[TBL] [Abstract] [Full Text] [Related]
3. Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines.
Zhai J; Li C; Sun B; Wang S; Cui Y; Gao Q; Sang F
Bioorg Med Chem Lett; 2022 Dec; 78():129041. PubMed ID: 36332882
[TBL] [Abstract] [Full Text] [Related]
4. vhl tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.
Todorović L; Stanojević B
Biomol Biomed; 2023 Feb; 23(1):26-36. PubMed ID: 36036061
[TBL] [Abstract] [Full Text] [Related]
5. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract] [Full Text] [Related]
6. Targeted Degradation of mRNA Decapping Enzyme DcpS by a vhl-Recruiting PROTAC.
Swartzel JC; Bond MJ; Pintado-Urbanc AP; Daftary M; Krone MW; Douglas T; Carder EJ; Zimmer JT; Maeda T; Simon MD; Crews CM
ACS Chem Biol; 2022 Jul; 17(7):1789-1798. PubMed ID: 35749470
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
[TBL] [Abstract] [Full Text] [Related]
8. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract] [Full Text] [Related]
9. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic leukemia: A Meta-Analysis of Randomized-Controlled Studies.
Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (vhl) E3 Ubiquitin Ligase.
Zhao Q; Ren C; Liu L; Chen J; Shao Y; Sun N; Sun R; Kong Y; Ding X; Zhang X; Xu Y; Yang B; Yin Q; Yang X; Jiang B
J Med Chem; 2019 Oct; 62(20):9281-9298. PubMed ID: 31539241
[TBL] [Abstract] [Full Text] [Related]
12. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Farnaby W; Koegl M; Roy MJ; Whitworth C; Diers E; Trainor N; Zollman D; Steurer S; Karolyi-Oezguer J; Riedmueller C; Gmaschitz T; Wachter J; Dank C; Galant M; Sharps B; Rumpel K; Traxler E; Gerstberger T; Schnitzer R; Petermann O; Greb P; Weinstabl H; Bader G; Zoephel A; Weiss-Puxbaum A; Ehrenhöfer-Wölfer K; Wöhrle S; Boehmelt G; Rinnenthal J; Arnhof H; Wiechens N; Wu MY; Owen-Hughes T; Ettmayer P; Pearson M; McConnell DB; Ciulli A
Nat Chem Biol; 2019 Jul; 15(7):672-680. PubMed ID: 31178587
[TBL] [Abstract] [Full Text] [Related]
13. Bilateral advanced (group D or E) intraocular retinoblastoma: outcomes in 72 Asian Indian patients.
Kaliki S; Mittal P; Mohan S; Chattannavar G; Jajapuram SD; Mohamed A; Palkonda VAR
Eye (Lond); 2019 Aug; 33(8):1297-1304. PubMed ID: 30932036
[TBL] [Abstract] [Full Text] [Related]
14. vhl-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway.
Yamaguchi R; Harada H; Hirota K
Tumour Biol; 2016 Oct; 37(10):13295-13306. PubMed ID: 27460078
[TBL] [Abstract] [Full Text] [Related]
15. HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Kim MJ; Kim DE; Jeong IG; Choi J; Jang S; Lee JH; Ro S; Hwang JJ; Kim CS
Anticancer Res; 2012 Aug; 32(8):3161-8. PubMed ID: 22843888
[TBL] [Abstract] [Full Text] [Related]
16. Cancer and leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
Rini BI; Halabi S; Taylor J; Small EJ; Schilsky RL;
Clin Cancer Res; 2004 Apr; 10(8):2584-6. PubMed ID: 15102658
[TBL] [Abstract] [Full Text] [Related]
17. Targeting of the vhl-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy.
Sosman JA
J Am Soc Nephrol; 2003 Nov; 14(11):2695-702. PubMed ID: 14569078
[TBL] [Abstract] [Full Text] [Related]
18. Shedding of CD9 antigen into cerebrospinal fluid by acute lymphoblastic leukemia cells.
Komada Y; Ochiai H; Shimizu K; Azuma E; Kamiya H; Sakurai M
Blood; 1990 Jul; 76(1):112-6. PubMed ID: 2364164
[TBL] [Abstract] [Full Text] [Related]
19. A monoclonal antibody (SJ-9A4) to P24 present on common alls, neuroblastomas and platelets - I. Characterization and development of a unique radioimmunometric assay.
Komada Y; Peiper SC; Melvin SL; Metzger DW; Tarnowski BH; Green AA
Leuk Res; 1983; 7(4):487-98. PubMed ID: 6578390
[TBL] [Abstract] [Full Text] [Related]
